BOOK
Adjunctive Technologies in the Management of Head and Neck Pathology, An Issue of Oral and Maxillofacial Clinics of North America, E-Book
(2014)
Additional Information
Book Details
Abstract
Adjunctive Technologies in the Management of Head and Neck Pathology, An Issue of Oral and Maxillofacial Clinics of North America, E-Book
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Adjunctive Technologies in the Management of Head and\rNeck Pathology | i | ||
| copyright\r | ii | ||
| Contributors | iii | ||
| Contents | v | ||
| Oral And Maxillofacial Surgery\rClinics Of North America\r | viii | ||
| Preface\r | ix | ||
| Epidemiologic Trends in Head and Neck Cancer and Aids in Diagnosis | 123 | ||
| Key points | 123 | ||
| Changing epidemiology of head and neck cancer | 123 | ||
| Incidence | 123 | ||
| Risk factors for HNSCC | 124 | ||
| Tobacco, Alcohol, Pan | 124 | ||
| HPV | 124 | ||
| Other Contributing Factors | 125 | ||
| Diseases and syndromes associated with increased risk for HNSCC | 125 | ||
| Plummer-Vinson | 125 | ||
| Fanconi Anemia and Dyskeratosis Congenita | 125 | ||
| Age, sex, and race predilection of HNSCC | 125 | ||
| Anatomic sites of HNSCC | 126 | ||
| Tongue | 126 | ||
| Floor of Mouth | 126 | ||
| Precursor lesions of HNSCC | 126 | ||
| Premalignant Lesion | 126 | ||
| Premalignant Condition | 126 | ||
| Leukoplakia | 126 | ||
| Proliferative Verrucous Leukoplakia | 128 | ||
| Erythroplakia | 129 | ||
| Oral Submucous Fibrosis | 129 | ||
| Oral Lichen Planus | 129 | ||
| Autofluorescence tissue-imaging devices for screening of HNSCC and its precursors | 130 | ||
| Oral epithelial dysplasia | 131 | ||
| Prediction of prognosis, treatment response, and survival in head and neck cancer | 133 | ||
| Biopsy Evaluation | 133 | ||
| Histologic Subtypes of SCC | 133 | ||
| Conventional/keratinizing SCC | 133 | ||
| HPV-associated SCC (HPV+ OPSCC) | 133 | ||
| Verrucous carcinoma | 134 | ||
| Papillary squamous carcinoma | 134 | ||
| Basaloid squamous carcinoma | 134 | ||
| Sarcomatoid squamous carcinoma (spindled cell carcinoma) | 136 | ||
| Histopathology prognosticators in SCC | 136 | ||
| Margins | 137 | ||
| Lymph Node Metastases and Extracapsular Extension | 137 | ||
| Tumor staging | 138 | ||
| Diagnostically relevant immunohistochemical stains for head and neck pathology | 138 | ||
| Immunohistochemistry | 138 | ||
| Makers for Infections | 138 | ||
| Prognostic biomarkers for HNSCC | 138 | ||
| HPV and p16 | 138 | ||
| Molecular alterations in HNSCC | 139 | ||
| Tp53 and EGFR | 139 | ||
| Acknowledgments | 139 | ||
| References | 139 | ||
| Use of Porous Space Maintainers in Staged Mandibular Reconstruction | 143 | ||
| Key points | 143 | ||
| Introduction | 143 | ||
| Clinical challenge | 143 | ||
| Technical innovations | 144 | ||
| Advantages of porous space maintainers | 144 | ||
| Implant fabrication | 145 | ||
| Case series | 145 | ||
| Clinical outcomes | 146 | ||
| Summary | 148 | ||
| References | 148 | ||
| Pitfalls in Determining Head and Neck Surgical Margins | 151 | ||
| Key points | 151 | ||
| Introduction | 151 | ||
| Historical perspective | 151 | ||
| Oral cavity cancer epidemiology | 152 | ||
| Margin assessment | 152 | ||
| Margin Measurements | 152 | ||
| Anatomic and Histologic Margins | 152 | ||
| Meeting with Pathologist: Tumor Mapping | 154 | ||
| Pathologic Assessment of Margins: Techniques | 155 | ||
| Bone Margins | 155 | ||
| Tissue Shrinkage | 156 | ||
| Excision Method | 157 | ||
| Good Margins | 157 | ||
| Margin Reporting | 157 | ||
| Therapeutic implications of positive margins | 158 | ||
| Future directions | 159 | ||
| Summary | 160 | ||
| References | 160 | ||
| Chemotherapy for Oral and Maxillofacial Tumors: An Update | 163 | ||
| Key points | 163 | ||
| Chemotherapy for early-stage disease | 164 | ||
| Chemotherapy for locally advanced resectable disease | 164 | ||
| Role of Neoadjuvant Chemotherapy | 164 | ||
| Role of Adjuvant Chemotherapy | 164 | ||
| Chemotherapy for locally advanced unresectable disease | 164 | ||
| Induction Chemotherapy Before Radiation Versus Radiation | 164 | ||
| Induction Chemotherapy Before Concurrent Chemoradiation | 165 | ||
| Role of Epidermal Growth Factor Inhibitors | 165 | ||
| Chemotherapy for metastatic or recurrent disease | 165 | ||
| Cytotoxic Chemotherapy | 165 | ||
| Targeted Therapy | 166 | ||
| Rare tumors | 166 | ||
| Osteosarcoma | 166 | ||
| Lymphoma | 167 | ||
| Giant Cell Tumor of the Jaw | 167 | ||
| Summary | 167 | ||
| Acknowledgments | 167 | ||
| References | 167 | ||
| Anti-Resorptive Osteonecrosis of the Jaws | 171 | ||
| Key points | 171 | ||
| Introduction | 171 | ||
| Osteonecrosis of the jaws is seen in patients without cancer who are naive to antiresorptive medications | 172 | ||
| Osteonecrosis of the jaws is seen in higher incidences in patients with cancer | 174 | ||
| Tori and exostoses are at-risk structures in patients taking antiresorptive medications and in those patients naive to anti ... | 177 | ||
| Untreated osteonecrosis of the jaws progresses to more advanced stages | 180 | ||
| Resection represents effective and first-line therapy for patients with osteonecrosis of the jaws | 181 | ||
| Mandibular segmental defects can be reconstructed in patients exposed to bisphosphonate medications | 184 | ||
| Teeth may be extracted in patients exposed to bisphosphonate medications without the subsequent development of osteonecrosis | 186 | ||
| Summary | 188 | ||
| References | 188 | ||
| Oral Surgery in Patients Undergoing Chemoradiation Therapy | 193 | ||
| Key points | 193 | ||
| Epidemiology | 194 | ||
| Chemotherapy | 194 | ||
| Radiation therapy | 194 | ||
| Preparations before the start of therapy | 195 | ||
| The Patient Receiving Chemotherapy | 195 | ||
| The Patient Receiving Radiation to the Head and Neck Region | 195 | ||
| Patient management during antineoplastic therapy | 198 | ||
| Myelosuppression | 198 | ||
| Mucositis | 198 | ||
| Neurotoxicity and Taste Alteration | 199 | ||
| Xerostomia | 200 | ||
| After chemotherapy and radiation therapy | 200 | ||
| Trismus | 200 | ||
| Prevention and treatment of osteonecrosis of the jaw bone | 201 | ||
| Oral Surgery in Irradiated Jaws | 202 | ||
| Prophylactic Hyperbaric Oxygen Therapy | 202 | ||
| ORN: Classification and Treatment | 203 | ||
| Dental Implant Placement After Radiation Therapy to the Head and Neck Region | 203 | ||
| Summary | 205 | ||
| References | 205 | ||
| Evaluation and Staging of the Neck in Patients with Malignant Disease | 209 | ||
| Key points | 209 | ||
| Introduction | 209 | ||
| TNM classification and staging | 210 | ||
| Considerations for N staging | 211 | ||
| Squamous cell carcinoma | 212 | ||
| Salivary gland cancers | 213 | ||
| Carcinoma of unknown primary | 213 | ||
| Evaluation of the neck for nodal metastasis | 214 | ||
| Ultrasound | 214 | ||
| CT and MRI Evaluation of the Neck | 214 | ||
| PET/CT | 216 | ||
| Sentinel Lymph Node Biopsy | 217 | ||
| Neck Evaluation During Post-therapeutic Surveillance | 217 | ||
| References | 218 | ||
| Update in Radiation Therapy for Oral and Maxillofacial Tumors and Dose Mapping | 223 | ||
| Key points | 223 | ||
| Introduction | 223 | ||
| Toxicity from RT | 227 | ||
| Summary | 228 | ||
| References | 228 | ||
| The Role of Bisphosphonates in Medical Oncology and Their Association with Jaw Bone Necrosis | 231 | ||
| Key points | 231 | ||
| The role of bisphosphonates in medical oncology | 231 | ||
| Mechanism of Action | 231 | ||
| Types of Bisphosphonates | 232 | ||
| Administration and Side Effects | 232 | ||
| Route of administration | 232 | ||
| Side effects | 232 | ||
| Absorption and half-life | 232 | ||
| Bisphosphonates in Multiple Myeloma | 232 | ||
| Bisphosphonates in Solid Tumors | 233 | ||
| Bisphosphonates in Metabolic Disorders | 233 | ||
| Other Bone-Modifying Agents | 233 | ||
| Associated risk of jaw bone necrosis with bisphosphonates | 234 | ||
| Pathogenesis | 234 | ||
| Acknowledgments | 235 | ||
| References | 235 | ||
| Nuclear Medicine Imaging Studies in the Diagnosis of Head and Neck Disease | 239 | ||
| Key points | 239 | ||
| Introduction to PET/CT imaging | 239 | ||
| Technical aspects of PET imaging | 241 | ||
| Typical images | 242 | ||
| PET imaging in DIONJ | 243 | ||
| References | 244 | ||
| Pharmacologic Modalities in the Treatment of Osteoradionecrosis of the Jaw | 247 | ||
| Key points | 247 | ||
| Introduction | 247 | ||
| Pathogenesis | 247 | ||
| Pharmacologic agents in ORN management | 249 | ||
| Hyperbaric Oxygen Therapy | 249 | ||
| Pentoxifylline and Tocopherol | 250 | ||
| Pentoxifylline | 250 | ||
| Tocopherol | 250 | ||
| Clodronate | 250 | ||
| Pentoxifylline and Tocopherol Combined Therapy With or Without Clodronate | 250 | ||
| Summary | 251 | ||
| References | 252 | ||
| Magnetic Resonance Imaging (MRI) in the Diagnosis of Head and Neck Disease | 253 | ||
| Key points | 253 | ||
| Introduction | 253 | ||
| Approach | 253 | ||
| Applications | 254 | ||
| Neoplasms and Masses | 254 | ||
| Infections | 254 | ||
| Skull Base and Temporal Bones | 260 | ||
| Vascular Lesions | 260 | ||
| Brachial Plexus | 267 | ||
| Summary | 268 | ||
| References | 268 | ||
| Index | 271 |